Neurocrine Biosciences
NBIX
#1203
Rank
A$24.73 B
Marketcap
$244.32
Share price
-0.96%
Change (1 day)
12.77%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $2.98

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.15. In 2022 the company made an earnings per share (EPS) of $2.59 an increase over its 2021 EPS that were of $1.53.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$2.9814.96%
2022$2.5969.47%
2021$1.53-78.21%
2020$7.02990%
2019$0.6481.82%
2018$0.35-113.5%
2017-$2.620.62%
2016-$2.6157.28%
2015-$1.6625.61%
2014-$1.3218.84%
2013-$1.11-1085.71%
2012$0.11-89.71%
2011$1.09-500%
2010-$0.27-86.92%
2009-$2.09-43.48%
2008-$3.70-57.8%
2007-$8.7792.58%
2006-$4.55371.67%
2005-$0.97-52.76%
2004-$2.0436.56%
2003-$1.50-70%
2002-$4.99118.31%
2001-$2.298.4%
2000-$2.1148.86%
1999-$1.42-20%
1998-$1.77-479.31%
1997$0.47

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.36 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.89-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.76-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$8.74 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.92 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.99-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.76-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.88-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA